FindTrial
Sign In

A Rollover Study to Follow the Long-term Durability of Response to UGN-103 in Participants From Study BL013

Status
Not yet recruiting
Phases
Phase 4
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2026-526359-75-00
Enrollment
13
Registered
2026-09-11
Start date
Unknown
Completion date
Unknown
Last updated
2026-09-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-Muscle Invasive Bladder Cancer

Brief summary

Duration of response (DOR)

Interventions

DRUGUGN-103 (Mitomycin)

Sponsors

Urogen Pharma Ltd.
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
Duration of response (DOR)—

Outcome results

None listed

Source: EU CTIS · Data processed: Sep 12, 2026